These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10539798)

  • 1. Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial.
    Abraira C; McGuire DK
    Am Heart J; 1999 Nov; 138(5 Pt 1):S360-5. PubMed ID: 10539798
    [No Abstract]   [Full Text] [Related]  

  • 2. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.
    Emanuele N; Klein R; Abraira C; Colwell J; Comstock J; Henderson WG; Levin S; Nuttall F; Sawin C; Silbert C; Lee HS; Johnson-Nagel N
    Diabetes Care; 1996 Dec; 19(12):1375-81. PubMed ID: 8941467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM.
    Colwell JA
    Ann Intern Med; 1996 Jan; 124(1 Pt 2):131-5. PubMed ID: 8554205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.
    Abraira C; Duckworth W; McCarren M; Emanuele N; Arca D; Reda D; Henderson W;
    J Diabetes Complications; 2003; 17(6):314-22. PubMed ID: 14583175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes.
    Abraira C; Colwell J; Nuttall F; Sawin CT; Henderson W; Comstock JP; Emanuele NV; Levin SR; Pacold I; Lee HS
    Arch Intern Med; 1997 Jan; 157(2):181-8. PubMed ID: 9009975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
    Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
    Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postprandial hyperglycaemia--its importance and implications.
    Lüddeke HJ
    Int J Clin Pract Suppl; 1999 Jul; 104():3-7; discussion 18-20. PubMed ID: 12669731
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
    Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
    Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM).
    Pitale SU; Abraira C; Emanuele NV; McCarren M; Henderson WG; Pacold I; Bushnell D; Colwell JA; Nuttall FQ; Levin SR; Sawin CT; Comstock JP; Silbert CK
    Diabetes Care; 2000 Sep; 23(9):1316-20. PubMed ID: 10977025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM).
    Azad N; Emanuele NV; Abraira C; Henderson WG; Colwell J; Levin SR; Nuttall FQ; Comstock JP; Sawin CT; Silbert C; Rubino FA
    J Diabetes Complications; 1999; 13(5-6):307-13. PubMed ID: 10765007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM).
    Agrawal L; Emanuele NV; Abraira C; Henderson WG; Levin SR; Sawin CT; Silbert CK; Nuttall FQ; Comstock JP; Colwell JA
    Diabetes Care; 1998 Apr; 21(4):510-5. PubMed ID: 9571333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM).
    Abraira C; Emanuele N; Colwell J; Henderson W; Comstock J; Levin S; Nuttall F; Sawin C
    Diabetes Care; 1992 Nov; 15(11):1560-71. PubMed ID: 1308130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.
    Bao YQ; Zhou J; Zhou M; Cheng YJ; Lu W; Pan XP; Tang JL; Lu HJ; Jia WP
    Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):564-8. PubMed ID: 20082624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.
    Reaven PD; Moritz TE; Schwenke DC; Anderson RJ; Criqui M; Detrano R; Emanuele N; Kayshap M; Marks J; Mudaliar S; Harsha Rao R; Shah JH; Goldman S; Reda DJ; McCarren M; Abraira C; Duckworth W;
    Diabetes; 2009 Nov; 58(11):2642-8. PubMed ID: 19651816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide.
    Skoff RA; Waterbury NV; Shaw RF; Egge JA; Cantrell M
    J Manag Care Pharm; 2011 Nov; 17(9):664-71. PubMed ID: 22050391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
    Cook W; Minervini G; Bryzinski B; Hirshberg B
    Postgrad Med; 2014 Oct; 126(6):19-32. PubMed ID: 25414932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus.
    Kitabchi AE; Kaminska E; Fisher JN; Sherman A; Pitts K; Bush A; Bryer-Ash M
    Am J Med Sci; 2000 Mar; 319(3):143-8. PubMed ID: 10746824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.